Show simple item record

dc.contributor.authorTimmins, Matthew A
dc.contributor.authorRingshausen, Ingo
dc.date.accessioned2022-05-14T01:06:07Z
dc.date.available2022-05-14T01:06:07Z
dc.date.issued2022-03-31
dc.identifier.issn2072-6694
dc.identifier.other35406544
dc.identifier.otherPMC8996985
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/337154
dc.description.abstractTransforming growth factor-beta (TGFB) is a critical regulator of normal haematopoiesis. Dysregulation of the TGFB pathway is associated with numerous haematological malignancies including myelofibrosis, acute myeloid leukaemia, and lymphoid disorders. TGFB has classically been seen as a negative regulator of proliferation in haematopoiesis whilst stimulating differentiation and apoptosis, as required to maintain homeostasis. Tumours frequently develop intrinsic resistant mechanisms to homeostatic TGFB signalling to antagonise its tumour-suppressive functions. Furthermore, elevated levels of TGFB enhance pathogenesis through modulation of the immune system and tumour microenvironment. Here, we review recent advances in the understanding of TGFB signalling in B-cell malignancies with a focus on the tumour microenvironment. Malignant B-cells harbour subtype-specific alterations in TGFB signalling elements including downregulation of surface receptors, modulation of SMAD signalling proteins, as well as genetic and epigenetic aberrations. Microenvironmental TGFB generates a protumoural niche reprogramming stromal, natural killer (NK), and T-cells. Increasingly, evidence points to complex bi-directional cross-talk between cells of the microenvironment and malignant B-cells. A greater understanding of intercellular communication and the context-specific nature of TGFB signalling may provide further insight into disease pathogenesis and future therapeutic strategies.
dc.languageeng
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcenlmid: 101526829
dc.sourceessn: 2072-6694
dc.titleTransforming Growth Factor-Beta Orchestrates Tumour and Bystander Cells in B-Cell Non-Hodgkin Lymphoma.
dc.typeArticle
dc.date.updated2022-05-14T01:06:06Z
prism.issueIdentifier7
prism.publicationNameCancers
prism.volume14
dc.identifier.doi10.17863/CAM.84573
rioxxterms.versionofrecord10.3390/cancers14071772
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidTimmins, Matthew A [0000-0002-7127-7395]
dc.contributor.orcidRingshausen, Ingo [0000-0002-7247-311X]


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International